Resonant Capital Advisors LLC Grows Position in Eli Lilly and Company $LLY

Resonant Capital Advisors LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 7.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,123 shares of the company’s stock after buying an additional 410 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $5,632,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Clare Market Investments LLC bought a new position in shares of Eli Lilly and Company during the first quarter valued at about $3,877,000. Sather Financial Group Inc increased its holdings in Eli Lilly and Company by 33.8% during the 1st quarter. Sather Financial Group Inc now owns 277 shares of the company’s stock valued at $255,000 after purchasing an additional 70 shares during the period. Advance Capital Management Inc. increased its holdings in Eli Lilly and Company by 4.8% during the 1st quarter. Advance Capital Management Inc. now owns 479 shares of the company’s stock valued at $441,000 after purchasing an additional 22 shares during the period. Signet Private Wealth LLC raised its position in Eli Lilly and Company by 11.0% during the 1st quarter. Signet Private Wealth LLC now owns 2,495 shares of the company’s stock valued at $2,295,000 after purchasing an additional 247 shares during the last quarter. Finally, Halter Ferguson Financial Inc. raised its position in Eli Lilly and Company by 762.6% during the 1st quarter. Halter Ferguson Financial Inc. now owns 7,686 shares of the company’s stock valued at $7,069,000 after purchasing an additional 6,795 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY opened at $1,233.32 on Wednesday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,249.45. The firm’s 50-day simple moving average is $1,078.08 and its two-hundred day simple moving average is $1,030.27. The stock has a market cap of $1.16 trillion, a PE ratio of 43.81, a price-to-earnings-growth ratio of 1.49 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts anticipate that Eli Lilly and Company will post 35.74 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wolfe Research reissued an “outperform” rating and set a $1,350.00 target price on shares of Eli Lilly and Company in a research note on Thursday, May 21st. HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and dropped their price target for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Jefferies Financial Group boosted their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research report on Tuesday, June 9th. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,243.22.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: JPMorgan raised its price target on Eli Lilly to $1,400 from $1,300 and reiterated an overweight rating, signaling continued upside expectations for the stock. Benzinga report on JPMorgan price target raise
• Positive Sentiment: Shares hit a fresh 52-week high, reflecting momentum buying and strong investor enthusiasm around Lilly’s GLP-1 and obesity-treatment pipeline. CNBC report on Eli Lilly hitting 52-week high
• Positive Sentiment: Weak results from Kailera Therapeutics’ weight-loss pill IPO appear to have indirectly helped Lilly by reinforcing the market’s confidence in Lilly’s lead position in obesity drugs. Yahoo Finance article on Kailera setback and Lilly market cap
• Positive Sentiment: Commentary from Jim Cramer and other market-watch pieces remained constructive on biotech and Lilly’s growth story, suggesting investors still see the company as a core winner in the GLP-1 boom. 247WallSt Cramer commentary on Eli Lilly
• Neutral Sentiment: Several articles highlighted Lilly as a top healthcare stock to own and as a long-term growth story, but these were mainly opinion pieces rather than new company-specific developments. Motley Fool article on Eli Lilly stock
• Neutral Sentiment: Recent partnership and China-related business updates show Lilly is still actively managing its broader pipeline and regional strategy, but they appear less important than the obesity franchise news for today’s move. Yahoo Finance article on R&D collaboration and China rights transfer
• Negative Sentiment: Some coverage continues to point to regulatory and pricing-policy risks for Lilly, which could weigh on sentiment over time even as the stock remains strong now. Yahoo Finance article on regulatory and pricing policy challenges

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.